Global landscape and temporal trends in lifetime risk of colorectal cancer in 185 countries:a population-based studyOA
Objective:Colorectal cancer(CRC)is the third most common cancer and the second leading cause of cancer-related mortality worldwide.This study was aimed at estimating regional and national variations in lifetime CRC risk worldwide.Methods:CRC data were extracted from GLOBOCAN 2022,including 185 countries,and population and all-cause mortality data were sourced from the United Nations.The world was divided into 20 geographical regions and categorized by Human Development Index(HDI).Lifetime CRC risk was estimated with the life table method,adjusted for multiple primary cancers.Results:In 2022,the lifetime risks of developing and dying from CRC were 2.69%[95%confidence interval(CI):2.68±2.70]and 1.39%(95%CI:1.39±1.40),respectively.Men had a higher risk of colon cancer than rectal cancer,and higher CRC risk than women.Lifetime risk varied by region and HDI:regions with very high,high,moderate,and low HDI had incidence risks of 5.17%,2.75%,0.72%,and 0.57%,respectively,and mortality risks of 2.48%,1.50%,0.44%,and 0.41%,respectively.Australia/New Zealand had the highest incidence risk(7.41%,95%CI:7.30±7.52),and Northern Europe the highest mortality risk(3.28%,95%CI:3.24±3.32).Risks were stable before 40 years of age,peaked in middle age,and declined after 70 years of age.Temporally,Thailand had the highest increasing trend in lifetime risk,whereas the United States and Austria showed a decreasing trend.Conclusions:Lifetime CRC risk differs by subtype,sex,HDI,and geography,and residual risk gradually decreases with age.Targeted primary prevention strategies should be implemented in various countries and regions to mitigate CRC burden.
Li Li;Kexin Sun;Xiang Li;Yifei Yao;Hengxi Li;Shaoming Wang;Wanqing Chen;Rongshou Zheng
Office for Cancer Registry,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,ChinaOffice for Cancer Registry,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,ChinaOffice for Cancer Registry,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,ChinaOffice for Cancer Registry,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,ChinaOffice for Cancer Registry,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,ChinaOffice for Cancer Registry,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,ChinaOffice for Cancer Registry,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,ChinaOffice for Cancer Registry,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
医药卫生
Lifetime riskcolorectal cancerincidencemortalityepidemiology
《Cancer Biology & Medicine》 2026 (7)
P.1004-1015,12
supported by grants from Capital’s Funds for Health Improvement and Research(Grant No.CFH2024-2G-40214)the CAMS Innovation Fund for Medical Sciences(Grant No.2021-I2M-1-011)The Beijing High-Level Innovation and Entrepreneurship Talent Support Program,Leading Talent Projects(Grant No.G202513008)the National High Level Hospital Clinical Research Funding and Cooperation Fund of CHCAMS and SZCH(Grant No.CFA202201003)。
评论